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ABSTRACT
Vaccinia viruses (VACV) are a novel class of immune-oncolytic therapeutics and their mechanism of action 
is based both on their capacity to replicate selectively in cancer cells and to elicit danger signals that can 
boost anti-tumor immunity. We recently reported that the intratumor expression of MLKL, a necroptosis 
inducing factor, generates a protective anti-tumor immunity. Here, we combined both approaches to test 
the use of VACV to deliver MLKL into the tumor. We generated VACV vectors expressing MLKL and 
evaluated the effects of MLKL on antitumor efficacy. In vitro infection of cancer cells with MLKL-expressing 
vectors led to cell death with necroptotic hallmarks. In syngeneic mouse tumor models, VACV expressing 
MLKL induced an outstanding antitumor activity, which was associated with a robust immunity directed 
against neo-epitopes. In conclusion, delivery of MLKL by VACV vectors boosts the intrinsic anti-tumor 
properties of these viral vectors by promoting in situ immunogenic cell death of infected cancer cells.
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Introduction
The principle that it is possible to fight cancer by activating 
a patient’s own immune system is a very appealing para-
digm. In the last decade, cancer immunotherapies have 
emerged as new powerful weapons in the anticancer 
arsenal.1 However, many patients do not respond to these 
therapies2 and combinations with novel immunotherapies 
are being evaluated for achieving clinical responses in resis-
tant tumors.
In the last decade, new insights into the working mechan-
isms of some conventional anticancer treatments showed that 
cancer cells can die in an immunogenic way.3 Consequently, 
the capacity of anticancer therapeutics to induce immunogenic 
cell death (ICD) has emerged as a critical factor in eliciting 
antitumor responses.4 Necroptosis is a genetically regulated 
form of necrotic cell death with ICD features.5 The necroptotic 
pathway culminates with phosphorylation of mixed lineage 
kinase domain-like (MLKL) protein, which is subsequently 
recruited to the plasma membrane, which becomes destabilized 
and permeable.6 Recently, we demonstrated that intratumoral 
delivery of mRNA coding for MLKL induces potent antitumor 
immunity and antitumor activity in mouse tumor models.7
Oncolytic vaccinia viruses (VACV) showed initial promise 
for the treatment of tumors and their capacity to act as immu-
notherapeutic agents demonstrated as key in clinical trials.8 
Replication of VACV in tumors serves as a potent danger 
signal and results in lysis of tumor cells and release of cancer 
antigens.9 Combined, such mechanisms overcome the 
immune-suppressive tumor environment and can result in 
T cell responses targeting tumor antigens. However, candidate 
viruses tested to date demonstrated a suboptimal capacity to 
establish antitumor immunity in patients.10 In this work, we 
aimed to improve oncolytic VACV treatments by combining 
these vectors with the delivery of the necroptosis executioner 
MLKL. We demonstrated that intratumoral administration of 
VACV expressing MLKL activates potent antitumor T cell 
responses directed against tumor neo-antigens, and that such 
immunity mediates an outstanding improvement in antitumor 
efficacy.
Results and discussion
MLKL expression controlled by the P7.5late VACV 
promoter is compatible with unimpaired viral life cycle
In order to activate necroptosis-like tumor cell death after 
infection with oncolytic viruses, we generated a set of VACV 
vectors expressing mouse MLKL. As MLKL induces cell death, 
we hypothesized that MLKL expression at late stages of the 
viral life cycle would be necessary to allow for generation of 
progeny virus. Therefore, we evaluated the strong late VACV 
promoter P1111 and the moderate-strength late VACV promo-
ter P7.5late11,12 for the control of MLKL transcription. In 
addition, in order to test the influence of virus replication on 
antitumor activity, both replicating and non-replicating 
MLKL-expressing VACV vectors were constructed: the repli-
cation-competent recombinant VACV was based on VACV 
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strain Western Reserve with inactivated viral thymidine kinase 
(WR/TK-),13 and the non-replicating vector virus was based on 
the highly attenuated vaccine strain Modified Vaccinia virus 
Ankara (MVA).14
We observed that cells infected with VACV (WR/TK- or 
MVA) and transfected at the same time with the P11-MLKL 
DNA died at early time points and no foci of VACV replication 
could be detected. This toxic effect of MLKL can be observed in 
Figure 1a (left panel), where CEF (Chicken Embryo 
Fibroblasts) cells infected with MVA and transfected with the 
P11-MLKL plasmid expressed low levels of GFP (encoded by 
the P11-MLKL plasmid) and rapidly lost their fibroblast-like 
morphology to a typical dead cell rounded morphology. In 
contrast, this effect was milder when transfecting the P7.5late- 
MLKL construct (Figure 1a, right panel); such transfection 
readily allowed for the formation of recombinant viruses and 
the MLKL-expressing VACVs WR/TK-/MLKL and MVA/ 
MLKL could be clonally isolated and amplified. Figure 1b 
depicts a schematic diagram of such vectors. Expression of 
mouse MLKL from the novel viruses was evaluated by 
Western-blot assay in non-murine cell lines to avoid interfer-
ence of endogenous MLKL (Figure 1c). Although MLKL- 
expression cassettes are inserted in different loci within 
VACV genome (Figure 1b) and this can affect MLKL expres-
sion, similar amounts of MLKL expression were detected in 
CEF cells. This suggests that the lower amounts of MLKL 
produced following infection of HeLa cells with MVA/MLKL 
is likely the result of the abortive infection of MVA in these 
cells.
MLKL-expressing VACV vectors led to cell death with 
necroptotic hallmarks
We next compared the outcome of parental and MLKL-expressing 
VACV on cancer cells. Expression of MLKL by the late VACV 
promoter P7.5late did not interfere with the capacity of VACV to 
replicate in cancer cell lines (Figure 2a) or with the plaque size 
phenotype (Figure 2b). Very importantly, VACV expressing 
MLKL demonstrated a superior capacity to kill tumor cells com-
pared with their parental counterpart (Figure 2c-d).
Next, we tested whether infection of cancer cells with 
MLKL-expressing VACV results in necroptotic hallmarks. 
Higher levels of HMGB1 protein were detected in the super-
natant of cells infected with MLKL-expressing VACV vectors 
(Figure 2d). In addition, cancer cells infected with VACV 
Figure 1. Construction of VACVs expressing MLKL. (a) Fluorescent images of CEF 
cells 24 hours after infection with Vaccinia virus (VACV) MVA strain and transfec-
tion with a plasmid codifying for mouse MLKL under the control of P7.5Late or 
P11 promoters. Cells were infected with a MOI of 5 to allow 100% infection. GFP is 
codified by the transfected plasmid and is used to observe toxicity due to over-
expression of MLKL by the P11 promoter (scale bar = 100 μm). (b) Schematic 
diagram of WR/TK-/MLKL and MVA/MLKL recombinant viruses. (c) Confirmation of 
mouse MLKL expression. HeLa and CEF cells were infected with a MOI of 5 and, 
24 hours post-infection, a Western-blot analysis was performed. For the non- 
replicating MVA/MLKL vector infections were increased to MOI 10 in order to 
readily detect MLKL expression in HeLa cells.
Figure 2. VACV vectors expressing MLKL activate necroptosis-related phenotype in 
cancer cells. (a) Replication capacity in a panel of cancer cells. Different tumor cell lines 
were infected with viruses at a MOI of 1 and virus production was measured by plaque- 
assay 48 hours post-infection. Means +SD are plotted. (b) Plaque size in MA104 cells. 
MA104 cells were infected at a MOI of 0.05 and, 3 days after infection, the diameter of 
plaques was measured after dying with crystal violet. MVA vectors were not included in 
this experiment due to their inability to form plaques. The size of 12 representative 
plaques and mean ±SD are depicted. (c-d) Cytotoxicity in mouse tumor cell lines. Cells 
were infected with a MOI of 1 and, 3 days (c) or at different time points after infection (d), 
% of cells killed was evaluated. (e) Detection of necroptosis-related HMGB1 release. 
HMGB1 concentration detected by ELISA assay on supernatants of CT26 cells infected 
with a MOI of 5 with indicated viruses. (f) Images of CT26 cells 24 hours after infection 
with indicated viruses (MOI of 5). Necroptosis-related swelling of WR/TK-/MLKL-infected 
cells could be observed (black arrows, scale bar = 25 μm). *, p < .05 vs non-MLKL 
expressing counterpart.
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expressing MLKL resulted in a visually different cytopathic 
effect (Figure 2d, black arrows), with increased cell swelling 
(bigger cells with a different phase contrast under the micro-
scope). Both the release of intracellular HMGB1 and swelling 
of cells are associated with necroptosis activation.7,15
MLKL-expressing VACV activates systemic antitumor 
immune responses and improves antitumor activity
We eventually evaluated the impact on tumor growth of intratumoral 
injection of MLKL-expressing VACV in syngeneic B16 melanoma 
tumor model. WR/TK- expressing mouse MLKL could significantly 
delay tumor growth (Figure 3a-b) and highly increased the median 
survival time of mice (Figure 3c) compared to the control virus.
Moreover, we evaluated if the delivery of VACV expressing 
MLKL into a primary tumor could result in a systemic anti- 
tumor response. Therefore, we inoculated B16 cells in the left 
hand flank of mice and, 3 days later, in the right flank. After 
tumors were established in both sides, only the tumor in the left 
flank was treated with the indicated viruses and growth of the 
treated and untreated tumors were monitored. Same way as in 
Figure 3, VACV-mediated expression of MLKL, either via MVA 
or WR/TK-, greatly reduced the volume of directly injected 
tumors compared to their control counterpart (MVA or WR/ 
TK-)(Figure 4c). Importantly, a pronounced delay in the growth 
of the untreated distal tumor was observed in mice treated with 
VACV expressing MLKL, whereas treatment with the control 
MVA and WR/TK- strain did not affect the untreated tumor 
growth (Figure 4a-b). In addition, mice treated with the replica-
tive WR/TK-/MLKL were better protected against growth of 
a distal tumor than mice treated with MVA/MLKL, and overall 
survival was also significantly increased when treated with the 
replication-competent strain (Figure 4d). This indicates that 
replication of the vector does play an important role in the 
antitumor activity of oncolytic viruses. This finding is somewhat 
in contradiction with a recent report showing that intratumoral 
inoculation of inactivated replication-deficient VACV MVA is 
sufficient for achieving an optimal antitumor activity.16 Importantly, the B16 tumor model allows evaluation of neo- epitope specific T cell responses. By ELISPOT, we determined 
the T cell response directed against the major histocompat-
ibility complex (MHC) class II-restricted neo-epitope B16- 
M30 or its wild-type counterpart B16-WT30.17 VACV expres-
sing MLKL performed better than their control counterparts, 
showing pronounced reactivity against the neo-epitope but not 
responding against the wild type peptide (Figure 4e).
These results reinforce the idea that oncolytic vectors cur-
rently in use need to be further improved in order to elicit 
robust antitumor immunity. Different oncolytic vectors show 
certain levels of immunogenic cell death (ICD) activation, but 
most of them activate forms of ICD that are different from 
necroptosis; For example, Newcastle disease virus and 
Adenoviruses predominantly activate autophagy,18,19 and 
Semliki Forest virus activates immunogenic apoptosis.20 
VACV has previously been shown to activate events of necrop-
tosis in certain human cell lines, but such activation does not 
result in subsequent activation of tumor-associated antigen- 
specific T-cells.20 In this work, control VACV vectors elicited 
a poor antitumor immunity (Figure 4), confirming this hin-
drance. However, our results also highlight that modifying 
Figure 3. Intratumoral administration of MLKL-expressing vectors protects against 
primary tumor growth. C57BL/6 mice harboring subcutaneous B16 tumors were 
randomized and injected twice (days 0 and 4) with an intratumoral dose of 1 × 107 
plaque-forming units (pfu) of indicated viruses. Injection of PBS was used as 
a control. Tumor volume of individual animals (a), mean of treatments (b), and 
overall survival (c) are plotted for 5–8 mice/group +SD. *, p < .05; **, p < .01; ***, 
p < .001.
Figure 4. VACV-mediated delivery of the necroptosis inducer MLKL activates 
antitumor immunity. (a-b) Intratumoral administration of MLKL-expressing vec-
tors protects against distal tumors. C57BL/6 mice harboring a primary and 
a secondary (on the counterflank) B16 tumors were injected twice (days 0 
and 4) with an intratumoral dose into the primary tumor of 1 × 107 plaque- 
forming units (pfu) of indicated viruses. Tumor growth of the untreated secondary 
tumor of individual animals (a) and mean of treatments (b), tumor growth of the 
directly injected primary tumor (c), and overall survival (d) are plotted +SD for 5–8 
mice/group. (e) Intratumoral administration of MLKL-expressing vectors induces 
antitumor T cell responses directed against tumor neo-antigens. Mice harboring 
B16 tumors were treated twice (days 0 and 4) with an intratumoral dose of 
indicated viruses and, at day 8 after virus-administration, splenocytes were 
analyzed for their reactivity to indicated peptides by IFN-γ ELISPOT. Individual 
values of 5 mice/group and mean ±SD are plotted. *, p < .05; **, p < .01; ***, 
p < .001.
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such vectors to efficiently activate necroptosis is feasible. For 
such activation, we previously demonstrated the advantages of 
delivering the necroptosis mediator MLKL7; such delivery was 
via a mRNA and here we demonstrated that such delivery is 
also efficient via a viral vector. In the same way as with mRNA 
delivery, intratumoral injection of VACV vectors expressing 
MLKL demonstrated to successfully induce neo-epitope- 
specific T cell responses, which are able to control the growth 
of primary and distal tumors. Further combinations with 
immunotherapies are under study; both oncolytic VACV21 
and delivery of mRNA coding for MLKL7 have demonstrated 
to have synergistic anti-tumor effects with immune check point 
blockades, and combination with MLKL-expressing VACV is 
likely to result in outstanding antitumor efficacies.
In summary, delivery of MLKL into the tumor through a viral 
vector is feasible and results in improved anti-tumor responses. 
Further development of such agents and their combination with 
other immunotherapies are an interesting prospect for develop-
ing a therapy able to induce responses in wide range of patients.
Materials and methods
Mouse models
C57BL/6 mice were injected subcutaneously with 5 × 105 
B16 cells into the left flank. At day 6–10 after implantation, 
indicated viruses were injected intratumorally at a dose of 
1 × 107 pfu/mice. In a different experimental set-up, a sec-
ond tumor was implanted on the right flank of mice at day 
3 after primary implantation. Tumor sizes were measured 
every 2 days and tumor volume was calculated as the length 
x width x height (in mm3). Mice were euthanized when 
tumor volume reached 1000 mm3.
IFN-γ ELISPOT
For ELISPOT assay, splenocytes were prepared from C57BL/6 
mice bearing a B16 tumor and treated as indicated, and 
2.5 × 105 cells were cultured for 24 hours in anti-IFN-γ 
(Diaclone) pre-coated 96-well plates in the presence of 10 μg/ 
ml of peptide. The synthetic peptides used for restimulation 
were: B16-M30 mut (PSKPSFQEFVDWENVSPELNSTD 
QPFL) and B16-M30 WT (PSKPSFQEFVDWEKVSPELN 
STDQPFL) originated from gene Kif18b.17
Cells and viruses
MA104, B16, CT26, HeLa, and Renca cell lines were pur-
chased from the American Type Culture Collection 
(ATCC). Primary chicken embryo fibroblasts (CEF) were 
prepared from 10-day-old chicken embryos (SPF eggs, 
VALO). All cell lines were maintained in recommended 
culture media containing 5–10% fetal bovine serum and 
antibiotics at 37°C, 5% CO2.
All vector viruses used in this work (WR/TK-, WR/TK-/MLKL, 
MVA, MVA/MLKL) express the red fluorescent marker gene 
mCherry using the VACV-specific late promoter P11. 
Replication-competent VACV (WR/TK- and WR/TK-/MLKL) 
are based on the VACV strain Western Reserve (WR) with 
a truncated viral thymidine kinase (TK) gene. For the construction 
of WR/TK-/MLKL, heterologous gene sequences encoding the 
murine MLKL protein were inserted by guided homologous 
recombination into the TK gene locus to be expressed under 
transcriptional control of the VACV-specific modified late pro-
moter P7.5Late (Figure 1b). For generating MVA/MLKL, the 
P7.5Late-MLKL expression cassette was introduced by homolo-
gous recombination into the intergenic site between the viral genes 
MVA069 R and MVA070 L.22 Viruses were purified as previously 
described13 and titrated by plaque assay in CEF cells which allow 
for productive replication of MVA recombinant viruses.
Protein analysis
For evaluating MLKL expression, HeLa or CEF cells were infected at 
an MOI of 5 (PFU/cell) and, 24 hours after infection, whole-cell 
protein extracts were obtained. Samples were separated by 10% SDS- 
PAGE gel, transferred to a nitrocellulose membrane, and mouse 
MLKL protein was detected using a monoclonal anti-MLKL primary 
antibody (Rabbit, Cell Signaling) and a polyclonal anti-Rabbit con-
jugated with HRP (Goat, Cell Signaling). A monoclonal anti- 
GADPH antibody (Rabbit, Cell Signaling) was used for the loading 
control.
Enzyme-linked immunosorbent assay
A HMGB1 ELISA kit (Tecan) was used to determine HMGB1 
released after 24 hours of infection with indicated viruses 
(MOI of 5).
Virus growth and cytotoxicity assays
2x105 cells were seeded in 24-well plates and infected at an MOI of 1 
(PFU/cell) with indicated viruses. Four hours after infection, cultures 
were washed twice with PBS and incubated in fresh virus-free 
medium. Forty-eight h after infection cultures were harvested, fro-
zen-thawed thrice, and viral titers were determined by plaque assay in 
CEF cells.
Cytotoxicity assays were performed by seeding 5 × 104 cells 
per well in 96-well plates and infecting at an MOI of 1; at 
indicated time points, a nonradioactive cell proliferation 
assay kit (Promega) was used to stain the cultures and deter-
mine percentage of cells killed.
Statistical analyses
Standard Student’s t test (two-tailed) was used for analyzing results in 
Figure 2. For comparison of antitumor efficacies in Figure 3b, 4b, and 
4c, a Two-Way ANOVA and Bonferroni posttest was chosen. 
A One-Way ANOVA and Tukey’s Multiple Comparison test 
were used in Figure 4e. For comparison of survival curves, a log 
rank test was used. In all cases, significance was achieved if p < .05.
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